This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
BioMarin (BMRN) reports mixed second-quarter results with earnings missing estimates but sales beating the same.
BioMarin Pharmaceutical (BMRN) Q2 Earnings Miss Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of -29.41% and 3.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
by Zacks Equity Research
Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales in the second quarter. On the call, management is likely to comment on the launch preparation for pegvaliase.
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
by Zacks Equity Research
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) shares rose nearly 9% in the last trading session, amid huge volumes.
BioMarin Begins Pediatric Study on Achondroplasia Candidate
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.
Amgen Gets FDA Nod to Add ASPIRE Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gets FDA approval to add overall survival data from the phase III ASPIRE study on the label of its multiple myeloma drug, Kyprolis.
3 Biotech Stocks Up in the Past Month on Industry Turnaround
by Zacks Equity Research
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
Catalyst's Fridapse Gets Priority Review by FDA, Shares Up
by Zacks Equity Research
The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.
5 Biotech Stocks to Boost Your Portfolio's Health This Year
by Kinjel Shah
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.
Allergan Recalls Taytulla Oral Contraceptives, Stock Down
by Zacks Equity Research
Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.
Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod
by Zacks Equity Research
The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.
Here's Why Sarepta is Up More Than 60% So Far This Year
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.
BioMarin's Palynziq Gets FDA Approval for Phenylketonuria
by Zacks Equity Research
BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.
BioMarin Begins Mid Stage Study on Gene Therapy Candidate
by Zacks Equity Research
BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.
Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y
by Zacks Equity Research
Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.
What's in the Cards for BioMarin (BMRN) in Q1 Earnings?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.
Catalyst Enrolls First Patient in Phase III Firdapse Study
by Zacks Equity Research
Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
by Zacks Equity Research
Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.